Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia 1

Interventions

Cyclophosphamide 89fludarabine phosphate 77Mycophenolic Acid 53Tacrolimus 52Peripheral Blood Stem Cell Transplantation 50Busulfan 44Whole-Body Irradiation 43Antilymphocyte Serum 41fludarabine 37Cyclosporine 36Filgrastim 32Melphalan 27Methotrexate 26Radiotherapy 23Cord Blood Stem Cell Transplantation 19Methylprednisolone 18Granulocyte Colony-Stimulating Factor 16Sirolimus 14Etoposide 13Alemtuzumab 12thymoglobulin 11sargramostim 11Stem Cell Transplantation 11Rituximab 11Thiotepa 9Azacitidine 8Cytarabine 7Psychiatric Rehabilitation 6Prednisone 6Flow Cytometry 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × siplizumab × Plasma cell × Clear all
NCT00113646 2018-03-16

Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

Massachusetts General Hospital

Phase 2 Terminated
14 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡